Résumé
We examine pharmaceutical regulations and incentives for innovation from an international perspective, highlighting the public good nature of healthcare innovation and its cross-border diffusion. We summarize the empirical evidence on how push and pull incentives shape R&D investment, innovation, and global access. We emphasize the role of strategic interdependencies and spillovers, including free-riding in R&D financing, learning-by-doing effects, drug short- ages, reference pricing, and parallel trade. We then provide new evidence on the international spillovers of pull incentives on innovation, showing that international cooperation and innova- tive institutions are necessary to better align national regulations with the global objective of sustaining pharmaceutical innovation.
Mots-clés
Pharmaceutical Regulation, Innovation, R&D, International Spillovers;
Codes JEL
- L10: General
- L20: General
- I10: General
- I11: Analysis of Health Care Markets
- I18: Government Policy • Regulation • Public Health
Remplace
Pierre Dubois, « Pharmaceutical Regulation and Incentives for Innovation in an International Perspective », TSE Working Paper, n° 25-1674, octobre 2025, révision décembre 2025.
Référence
Pierre Dubois, « Pharmaceutical Regulation and Incentives for Innovation in an International Perspective », 2025, à paraître.
Voir aussi
Publié dans
2025, à paraître
